Star Equity (STRR) Competitors $2.03 -0.01 (-0.49%) Closing price 03:52 PM EasternExtended Trading$2.03 0.00 (0.00%) As of 04:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock STRR vs. NEPH, TMDIF, COCH, DRIO, PYPD, NMTC, BDMD, LYRA, CLGN, and OSRHShould you be buying Star Equity stock or one of its competitors? The main competitors of Star Equity include Nephros (NEPH), Titan Medical (TMDIF), Envoy Medical (COCH), DarioHealth (DRIO), PolyPid (PYPD), NeuroOne Medical Technologies (NMTC), Baird Medical Investment (BDMD), Lyra Therapeutics (LYRA), CollPlant Biotechnologies (CLGN), and OSR (OSRH). These companies are all part of the "medical equipment" industry. Star Equity vs. Its Competitors Nephros Titan Medical Envoy Medical DarioHealth PolyPid NeuroOne Medical Technologies Baird Medical Investment Lyra Therapeutics CollPlant Biotechnologies OSR Nephros (NASDAQ:NEPH) and Star Equity (NASDAQ:STRR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation. Do institutionals & insiders hold more shares of NEPH or STRR? 41.1% of Nephros shares are owned by institutional investors. Comparatively, 3.8% of Star Equity shares are owned by institutional investors. 6.7% of Nephros shares are owned by company insiders. Comparatively, 33.5% of Star Equity shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has higher earnings and valuation, NEPH or STRR? Star Equity has higher revenue and earnings than Nephros. Star Equity is trading at a lower price-to-earnings ratio than Nephros, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNephros$15.52M2.64-$1.58M$0.0755.29Star Equity$57.17M0.11$25.13M-$3.43-0.59 Does the media favor NEPH or STRR? In the previous week, Nephros and Nephros both had 2 articles in the media. Nephros' average media sentiment score of 0.43 equaled Star Equity'saverage media sentiment score. Company Overall Sentiment Nephros Neutral Star Equity Neutral Does the MarketBeat Community believe in NEPH or STRR? Nephros received 9 more outperform votes than Star Equity when rated by MarketBeat users. However, 100.00% of users gave Star Equity an outperform vote while only 43.33% of users gave Nephros an outperform vote. CompanyUnderperformOutperformNephrosOutperform Votes1343.33% Underperform Votes1756.67% Star EquityOutperform Votes4100.00% Underperform VotesNo Votes Which has more volatility & risk, NEPH or STRR? Nephros has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500. Comparatively, Star Equity has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500. Do analysts prefer NEPH or STRR? Nephros currently has a consensus price target of $5.00, indicating a potential upside of 29.20%. Star Equity has a consensus price target of $5.00, indicating a potential upside of 146.31%. Given Star Equity's higher possible upside, analysts clearly believe Star Equity is more favorable than Nephros.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nephros 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Star Equity 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is NEPH or STRR more profitable? Nephros has a net margin of -6.86% compared to Star Equity's net margin of -12.41%. Star Equity's return on equity of -8.72% beat Nephros' return on equity.Company Net Margins Return on Equity Return on Assets Nephros-6.86% -11.39% -8.30% Star Equity -12.41%-8.72%-4.62% SummaryStar Equity beats Nephros on 9 of the 14 factors compared between the two stocks. Get Star Equity News Delivered to You Automatically Sign up to receive the latest news and ratings for STRR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding STRR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart STRR vs. The Competition Export to ExcelMetricStar EquityElectromedical equipment IndustryMulti-Sector SectorNASDAQ ExchangeMarket Cap$6.51M$3.33B$13.84B$8.50BDividend YieldN/A1.73%3.89%4.17%P/E Ratio-0.7919.2025.2019.64Price / Sales0.11195.882.98152.17Price / Cash6.1146.8413.3534.64Price / Book0.143.812.104.60Net Income$25.13M$95.96M$959.43M$248.06M7 Day Performance-4.69%6.80%-1.26%-1.02%1 Month Performance-9.78%16.19%3.23%3.51%1 Year Performance-51.23%33.72%-6.50%12.68% Star Equity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)STRRStar Equity2.8275 of 5 stars$2.03-0.5%$5.00+146.3%-51.7%$6.51M$57.17M-0.79460Short Interest ↑NEPHNephros1.8683 of 5 stars$3.13+15.1%$5.00+59.7%+84.8%$33.18M$15.52M-34.7830Short Interest ↑High Trading VolumeTMDIFTitan MedicalN/A$0.29-0.2%N/A+558.2%$32.73M$17.63M-0.2350Gap UpCOCHEnvoy Medical2.2729 of 5 stars$1.50-1.4%$9.25+516.7%-42.9%$31.99M$212K-1.0934Positive NewsShort Interest ↑DRIODarioHealth1.6863 of 5 stars$0.70-2.1%$2.00+185.7%-39.3%$31.13M$28.03M-0.74200PYPDPolyPid3.1266 of 5 stars$2.95+5.4%$11.33+284.2%-23.3%$30.06MN/A-0.5980Analyst RevisionHigh Trading VolumeNMTCNeuroOne Medical Technologies2.3506 of 5 stars$0.59-3.0%$1.45+144.6%-36.5%$29.54M$5.76M-2.2820Positive NewsHigh Trading VolumeBDMDBaird Medical InvestmentN/A$4.41+14.5%N/AN/A$29.04M$37.04M0.00N/AGap UpLYRALyra Therapeutics3.0592 of 5 stars$20.25+310.8%$100.00+393.8%-23.5%$26.83M$1.19M-13.5950Positive NewsShort Interest ↓Analyst RevisionGap DownHigh Trading VolumeCLGNCollPlant Biotechnologies2.7279 of 5 stars$2.28-28.3%$11.50+404.4%-67.1%$26.12M$2.47M-1.4870High Trading VolumeOSRHOSRN/A$1.31-9.7%N/AN/A$25.25M-$148.95K0.00N/APositive NewsGap Down Related Companies and Tools Related Companies Nephros Competitors Titan Medical Competitors Envoy Medical Competitors DarioHealth Competitors PolyPid Competitors NeuroOne Medical Technologies Competitors Baird Medical Investment Competitors Lyra Therapeutics Competitors CollPlant Biotechnologies Competitors OSR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:STRR) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Star Equity Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Star Equity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy STRR Stock Free STRR Stock Alerts